A Study of LY2608204 in Patients With Type 2 Diabetes

Safety and Tolerability of Multiple Ascending Doses of LY2608204 in Patients With Type 2 Diabetes Mellitus

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01247363

Enrollment

Registered

2010-11-24

Start date

2010-11-30

Completion date

2011-03-31

Last updated

2018-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Diabetes glucokinase safety

Brief summary

Safety study with multiple oral doses of LY2608204 given to patients with type 2 diabetes. Study subjects will receive once daily doses of LY2608204 for a total treatment duration of up to 28 days. In this study, each patient will receive increasing doses of LY2608204 until reaching the highest dose that they can tolerate. Continuous glucose monitoring devices will be employed for each patient to monitor for hypoglycemia during study treatment. Dose titration and dose reduction is determined for each individual patient based on their safety and glycemic data.

Interventions

DRUGLY2608204

Administered orally.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients diagnosed with Type 2 diabetes mellitus (T2DM) who are currently treated with diet/lifestyle measures alone or in combination with anti-diabetic agents, including insulins * Have fasting blood glucose (FBG) greater than or equal to 160 milligram/deciliter (mg/dL), with a subset of patients with FBG greater than or equal to 190 mg/dL in at least 2 measurements on separate days * Have a glycated haemoglobin (HbA1c) level of greater than or equal to 8% and less than or equal to 11% at screening * If female, are not of child-bearing potential due to surgical sterilisation (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause * Are males or females who are at least 18 years old (for sites outside of Singapore) or at least 21 years old (for sites within Singapore) but no more than 70 years old (for all sites) * Body mass index (BMI) greater than 18.5 kilogram/square meter (kg/m²) and less than 40.0 kg/m² * Have clinical laboratory test results within the normal range for the population or investigator site, or with abnormalities deemed clinically insignificant by the investigator * Have supine systolic blood pressure (SBP) greater than 160 millimeters of mercury (mmHg) and supine diastolic blood pressure (DBP) less than 100 mmHg * Have venous access sufficient to allow blood sampling as per the protocol * Are willing and able to comply with requirements for continuous glucose monitoring (CGM) * Are reliable and willing to make themselves available for the duration of the study and who will abide by the Clinical Research Unit (CRU) policy and procedure and study restrictions. This includes staying in-patient at the CRU for a total duration of up to 31 days * Have given written informed consent approved by Lilly and the ethical review board governing the site

Exclusion criteria

* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or use of a drug or device other than the study drug used in this study, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study * Have significant history of past or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (other than diabetes), hematological, or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs or of constituting a risk when taking the study drug formulations or interfering with the interpretation of data * Have a history of a seizure disorder * A corrected QT interval greater than 450 milliseconds (msec) at screening or any personal history of ventricular tachycardia or unexplained syncope, or other abnormality in the 12-lead Electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study * Have family history of long QT syndrome or family history of sudden unexplained death * Use medications known to prolong the QT interval. * Have type 1 diabetes mellitus or a history of ketoacidosis or any other type of diabetes mellitus other than type 2 * Use of any known inducers or inhibitors of CYP3A within 14 days prior to the first dosing with study drug or intended use during the study * History of a hypoglycemic event with acute mental status alteration that was not preceded by prodromal symptoms recognizable to the patient * Fasting serum triglycerides greater than 500mg/dl * Serum creatinine greater than 1.3 mg/dL in women, greater than 1.5 mg/dL in men * Clinical evidence of active diabetic proliferative retinopathy * Known clinically significant autonomic neuropathy as evidenced by urinary retention, orthostatic hypotension, diabetic diarrhea or gastroparesis * Clinically significant coronary events or symptoms within 6 months prior to study entry * Clinically significant peripheral vascular disease * Have known allergies to LY2608204 or related compounds * Evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies/antigen * Evidence of hepatitis B and/or positive hepatitis B surface antigen (HBsAg) * Donation or loss of blood equal to or exceeding 450 milliliter (mL) during the 3 months before the first administration of study drug * Patients who have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females) (1 unit equal to 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits) or patients unwilling to stop alcohol consumption 24 hours prior to admission until the completion of each in-patient study period * Patients who smoke more than 10 cigarettes or other tobacco products per day before study entry. Patients will not be allowed to smoke while in the study Unit * Have a history of drug or alcohol abuse * Intended use of over-the counter or prescription medications 7 and 14 days, respectively, prior to dosing. If this situation arises, inclusion of an otherwise suitable volunteer may be at the discretion of the investigator. Use of anti-diabetic medication \[metformin, sulphonylureas, glinides, thiazolidinediones, acarbose, DPPIV inhibitors, Byetta (but not liraglutide)\] by patients with type 2 diabetes mellitus is acceptable for this study * Have repeated alanine transaminase levels greater than 2.5 times the upper limit of the reference range at screening, as determined by the central laboratory * Have previously been enrolled in this clinical study or any other study of LY2608204.

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants With Clinically Significant Adverse Effects	Day 1 through Day 49	Clinically significant adverse effects refer to any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the investigational product, whether or not related to the medicinal investigational product.

Secondary

Measure	Time frame	Description
Maximum Drug Concentration (Cmax)	Predose, 1, 2, 4, 6, 7, 10, 12, 24, 48, 120 and 168 hours Postdose	—
Area Under the Concentration Time Curve (AUC)	Predose, 1, 2, 4, 6, 7, 10, 12 and 24 hours Postdose	AUC for Day 1 is AUC from 0 to 24 hours. AUC for all other days is AUC at a dosing interval.
Time to Maximum Drug Concentration (Tmax)	Predose, 1, 2, 4, 6, 7, 10, 12, 24, 48, 120 and 168 hours Postdose	—
Number of Hypoglycemic Events	Day 1 through Day 29	Number of hypoglycemia events with blood glucose concentration \<70 milligram/deciliter (mg/dL).

Countries

Singapore, United States

Participant flow

Participants by arm

Arm	Count
LY2608204 Oral capsules of LY2608204 given once daily at a starting dose of 160 mg, which was titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.	20
Total	20

Baseline characteristics

Characteristic	LY2608204
Age, Continuous	54.4 years STANDARD_DEVIATION 8.9
Fasting Blood Glucose (FBG)	233.5 milligram/deciliter (mg/dL) STANDARD_DEVIATION 38.61
Glycated Hemoglobin (HbA1c)	10.48 percentage of glycated hemoglobin STANDARD_DEVIATION 0.89
Race/Ethnicity, Customized Black or African American	2 Participants
Race/Ethnicity, Customized White	18 Participants
Region of Enrollment United States	20 Participants
Sex: Female, Male Female	7 Participants
Sex: Female, Male Male	13 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —
other Total, other adverse events	9 / 20	8 / 20	9 / 19	8 / 17
serious Total, serious adverse events	0 / 20	0 / 20	0 / 19	0 / 17

Outcome results

Primary

Number of Participants With Clinically Significant Adverse Effects

Clinically significant adverse effects refer to any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the investigational product, whether or not related to the medicinal investigational product.

Time frame: Day 1 through Day 49